Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Leptin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    84 result(s) found for: Leptin. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2017-003014-22 Sponsor Protocol Number: Thalamus_V3 Start Date*: 2018-06-25
    Sponsor Name:Medical University of Vienna
    Full Title: The role of leptin in regulating hepatic lipid metabolism in humans
    Medical condition: lipodystrophy patients, patients after liver transplantation and healthy controls
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000082-72 Sponsor Protocol Number: RC-P0054 Start Date*: 2019-01-03
    Sponsor Name:Groupement des Hôpitaux de l'Institut Catholique de Lille (GHICL)
    Full Title: Study of the communication of the hypothalamus with the periphery: impact of metformin on leptin transport in the cerebrospinal fluid of obese patients. A monocentric prospective study
    Medical condition: OBESITY (BMI > 30)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-005006-35 Sponsor Protocol Number: RM-493-022 Start Date*: 2018-05-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 recepto...
    Medical condition: Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Human Genetics studies have identified several diseases that are the result of genet...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004021-26 Sponsor Protocol Number: RRK 2768 Start Date*: 2005-10-06
    Sponsor Name:University Hospital Birmingham
    Full Title: Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic reg...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002005-36 Sponsor Protocol Number: RM-493-015 Start Date*: 2017-10-30
    Sponsor Name:Rhythm Pharmaceuticals, Inc.
    Full Title: An Open Label, 1-Year Trial, including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Leptin Receptor (LEPR) Deficiency...
    Medical condition: Early Onset Leptin Receptor (LEPR) Deficiency Obesity due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000138-33 Sponsor Protocol Number: R4461-PLD-20100 Start Date*: 2021-12-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy
    Medical condition: Familial Partial Lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10053857 Partial lipodystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-016382-29 Sponsor Protocol Number: P1736-05/34/09 Start Date*: 2009-11-06
    Sponsor Name:Piramal Life Sciences Limited
    Full Title: A Phase II, 12-Week Randomised, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate Safety, Tolerability, Pharmacokinetics and Effect On Glycemic Control of P1736-05 in Subjects wi...
    Medical condition: Diabetes mellitus, type 2 (Blood Glucose Lowering Effect)/
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015523-91 Sponsor Protocol Number: ENM-EA-011 Start Date*: 2010-01-21
    Sponsor Name:Medizinische Universiätsklinik Graz, Abteilung für Endokrinologie und Nuklearmedizin
    Full Title: Placebo controlled study on effects of vitamin D supplementation in healthy women and men on immunological, endocrine and metabolic parameters
    Medical condition: healthy volunteers. The intended indication for the investigated product is prevention and treatment of immunological (e.g. type 1 diabetes), endocrine (e.g. endocrine hypertension), metabolic (e.g...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004478-26 Sponsor Protocol Number: GHD/GHI Start Date*: 2006-01-13
    Sponsor Name:Karolinska universitetssjukhuset
    Full Title: Effects of growth hormone treatment to patients with partial growth hormone deficiency, with special emphasis on acute phase proteins and pro-inflammatory cytokines.
    Medical condition: Patients with various degrees of growth hormone (GH) insufficiency due to previously operated pituitary tumours.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001313-14 Sponsor Protocol Number: 2007-189-2 Start Date*: 2012-10-17
    Sponsor Name:Dutch growth research foundation
    Full Title: Young adult Prader-Willi Study Effects of Growth Hormone after final height: A clinical care study to the optimal dosage of growth hormone in young adults with PWS.
    Medical condition: Prader Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10041331 Somatotrophin LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004450-21 Sponsor Protocol Number: EMR200136-570 Start Date*: 2014-02-07
    Sponsor Name:Merck Serono S.p.A.
    Full Title: Multicenter, open-label, 12 weeks, phaseIV pRospectivE randomized study aimed at evaLuating whether sc IFN beta 1a (Rebif®) administered In the morning may affEct the severity of Flu-like syndrom...
    Medical condition: relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000871-17 Sponsor Protocol Number: GLP1 Start Date*: 2014-08-21
    Sponsor Name:Eva Marie Erfurth [...]
    1. Eva Marie Erfurth
    2. Lund University
    3. Lund University
    Full Title: Effects of Exenatid on Weigth during diet and Caloric Restriction in patients with Craniopharyngioma and Hypothalamic obesity
    Medical condition: Operated craniopharyngioma with hypothalamic involvement, Craniopharyngioma is a pituitary tumor that often affects the hypothalamus. These patients suffer from an intractable weight gain. This is ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004875-61 Sponsor Protocol Number: 15778303 Start Date*: 2016-02-05
    Sponsor Name:CHU TOULOUSE
    Full Title: Influence of apelin on insulin sensitivity in type 2 diabetic volunteers
    Medical condition: type 2 diabetes
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002224-15 Sponsor Protocol Number: Start Date*: 2009-01-09
    Sponsor Name:Göteborgs Universitet
    Full Title: Individual GH dosing using 1st year GH responsiveness for prepubertal growth response in short GHD/ISS children
    Medical condition: GHD+ISS in prepubertal children born at term or prematurely, AGA or SGA GHD and SGA children (phase IV study) ISS children (phase III study)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000956-32 Sponsor Protocol Number: 20022012 Start Date*: 2012-06-28
    Sponsor Name:St. Antonius Ziekenhuis
    Full Title: Pharmacokinetics of intravenous acetaminophen and its metabolites in morbidly obese patients
    Medical condition: Morbid obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-005083-25 Sponsor Protocol Number: GS-US-104-0318 Start Date*: 2005-08-12
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Phase IV, Randomized, Double-Blind, Placebo-Controlled Two-Phase Crossover Study of the Metabolic Impact of Tenofovir Disoproxil Fumarate on HIV 1 Seronegative Healthy Adult Males
    Medical condition: Human Immunodeficiency Virus (HIV-1) infection
    Disease: Version SOC Term Classification Code Term Level
    7.0 10020161 PT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003072-31 Sponsor Protocol Number: 2378 Start Date*: 2018-05-15
    Sponsor Name:VU University Medical Center
    Full Title: The effects of sex hormone administration on marrow and visceral adiposity
    Medical condition: Healthy transgender persons (the effect of differences in sex hormones on the amount of bone marrow fat)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002519-14 Sponsor Protocol Number: 2015-775 Start Date*: 2015-08-25
    Sponsor Name:Herlev Hospital
    Full Title: The MIRAD study - Mineralocorticoid Receptor Antagonists in Type 2 Diabetes. A randomised, double-blind, placebo-controlled study of the effect of Mineralocorticoid Receptor Antagonists in Type 2 D...
    Medical condition: diabetes (type 2)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-006114-14 Sponsor Protocol Number: 62326B1658 Start Date*: 2012-04-17
    Sponsor Name:Research and Development department
    Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr...
    Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004620-38 Sponsor Protocol Number: DOLU-FAT Start Date*: 2020-04-09
    Sponsor Name:Fundació Lluita contra la SIDA
    Full Title: Study to assess the effect of a Darunavir/Cobicistat-based regimen on weight and body composition in HIV-infected subjects who present weight gain during a dolutegravir-based regimen.
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 08:53:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA